In addition to the structural differences between GLP1 agonists and endogenous GLP1 peptide, GLP1RAs are structurally different from each other, giving them unique pharmacokinetic and pharmacodynamic characteristics
The drug works by suppressing appetite by mimicking the hormone glucagon-like peptide-1 (GLP-1), which is released after eating
Weight loss reduces metabolic rate and subcutaneous fat insulation, leading to increased cold sensitivity through adaptive thermogenesis
Genetic variants acting as proxies for GLP-1RAs show the lifelong effects of changes in HbA1c levels and GLP-1R gene expression on SA risk, and this impact may not be comparable to the short-term effects of glucose-lowering drugs
It is a reimbursement problem, and it is the binding commercial constraint on this entire category
Therefore, most GLP-1 agonists will perform better than Orlistat